ArcDia offers the mariPOC platform, an automated point‑of‑care antigen test that detects up to 11 respiratory, pharyngeal and gastrointestinal pathogens from a single sample. The instrument provides preliminary results in 15–20 minutes and full results within two hours, with built‑in autoverification and LIS/EHR integration for real‑time reporting and surveillance.
Funding
Funding not disclosed
Founders
Product
Problem
Acute respiratory, pharyngeal, and gastrointestinal infections present with overlapping symptoms, making it difficult to select appropriate therapy without laboratory confirmation. Conventional testing often requires centralized labs, multiple specimens, and long turnaround times, which delays treatment decisions and infection‑control measures. Limited access to rapid, multiplex diagnostics at point‑of‑care sites hampers pandemic response and routine flu‑season management.
Solution
ArcDia’s mariPOC platform delivers automated, syndromic antigen testing that identifies multiple pathogens from a single clinical sample in minutes. The instrument performs walk‑away analysis with built‑in autoverification, providing preliminary results in 15–20 minutes and definitive results within two hours. Its proprietary TPX technology detects pathogen‑specific proteins, enabling high‑sensitivity, CE‑marked IVD performance across viral, bacterial, and toxin targets. The system integrates with laboratory information systems (LIS) and the mariCloud™ analytics suite for real‑time reporting, cohorting, and epidemiological surveillance. Flexible test panels (single‑analyte or multi‑analyte Respi+, Pharyn, Quick Flu, Gastro, CDI) allow users to tailor testing to local prevalence and clinical workflow, supporting decentralized testing in pharmacies, urgent‑care clinics, and hospital emergency departments.
Target Audience
Primary users are point‑of‑care laboratories, urgent‑care and primary‑care clinics, hospital emergency departments, and pharmacy health points that require rapid, multiplex infectious‑disease diagnostics. Public‑health agencies also benefit from the integrated surveillance data.
Features
- Automated, walk‑away instrument with internal quality‑control and autoverification engine.
- Simultaneous detection of up to 11 respiratory pathogens (including SARS‑CoV‑2, influenza A/B, RSV, adenovirus, pneumococcus) in a single assay (Respi+ panel).
- TPX antigen‑detection technology that directly captures pathogen proteins, delivering laboratory‑grade sensitivity and specificity.
- Rapid turnaround: preliminary results in 15–20 min, full result set in ≤2 h.
- Flexible test configurations: single‑analyte, multi‑analyte, and high‑capacity formats for pandemic scaling.
- Seamless LIS/EHR connectivity via standard interfaces (e.g., HL7, FHIR) and optional cloud‑based mariCloud™ data aggregation for surveillance.
- CE‑marked IVD compliance, compatible with nasal and nasopharyngeal sampling, supporting self‑sampling workflows.